Nordion Reports Second Quarter 2011 Financial Results
Continued progress in value-creating business initiatives Nordion Highlights: — Strong second quarter year-over-year TheraSphere® revenue growth of 47% — Second quarter Sterilization Technologies revenue boosted by shipment of production irradiator — Received U.S. FDA approval to proceed with TheraSphere® Phase III trials for primary and metastatic liver cancer Nordion reports in U.S. dollars …
Read more on redOrbit
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
0 Comments.